No Data
Investors in Myriad Genetics (NASDAQ:MYGN) From Five Years Ago Are Still Down 51%, Even After 4.3% Gain This Past Week
Myriad Genetics to Present at 43rd Annual J.P. Morgan Healthcare Conference
The University Of Texas MD Anderson Cancer Center And Myriad Genetics Announce A 5-Year Strategic Alliance To Accelerate The Clinical Evaluation And Development Of Myriad's Molecular Residual Disease Assay
Myriad Genetics Issues Quality, Innovation, and Corporate Responsibility Report
Myriad Genetics, Inc.'s (NASDAQ:MYGN) Intrinsic Value Is Potentially 97% Above Its Share Price
Myriad Genetics' RiskScore Study Named One of the Top 10 Significant Advances in Genomic Medicine in American Journal of Human Genetics
905745367 OP : It will bounce back